Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan

Bone Marrow Transplantation volume 42, pages 135–136 (2008)Cite this article

Seizures are a well known side effect of BU administration, especially at the high doses used for pre-transplant conditioning regimens; they occur in 10% of adults and 7.5% of children, and are effectively prevented by an antiepileptic prophylaxis both in paediatric and adult population.1

The most commonly used drugs in this setting are diphenylhydantoin and carbamazepine, but these molecules are not active until a sufficient blood level is reached, which may take several days and frequent dose-titration. Furthermore, both these drugs may have relevant interactions with the metabolism of other medications commonly used during hematopoietic SCT (HSCT), including antibiotics or even BU itself.2

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990; 50: 6203–6207.

    CAS  PubMed  Google Scholar 

  2. Hassan M, Oberg G, Björkholm M, Wallin I, Lindgren M . Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181–186.

    Article  CAS  PubMed  Google Scholar 

  3. Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant 2002; 29: 963–965.

    Article  CAS  PubMed  Google Scholar 

  4. Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans affairs status epilepticus cooperative study group. N Engl J Med 1998; 339: 792–798.

    Article  CAS  PubMed  Google Scholar 

  5. Greenblatt DJ, von Moltke LL, Ehrenberg BL, Harmatz JS, Corbett KE, Wallace DW et al. Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. Crit Care Med 2000; 28: 2750–2757.

    Article  CAS  PubMed  Google Scholar 

  6. Dominguez KD, Crowley MR, Coleman DM, Katz RW, Wilkins DG, Kelly HW . Withdrawal from lorazepam in critically ill children. Ann Pharmacother 2006; 40: 1035–1039.

    Article  CAS  PubMed  Google Scholar 

  7. Henner WD, Furlong EA, Flaherty MD, Shea TC, Peters WP . Measurement of busulfan in plasma by high-performance liquid chromatography. J Chromatogr 1987; 416: 426–432.

    Article  CAS  PubMed  Google Scholar 

  8. Tran HT, Madden T, Petropoulos D, Worth LL, Felix EA, Sprigg-Saenz HA et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000; 26: 463–470.

    Article  CAS  PubMed  Google Scholar 

  9. Zwaveling J, Bredius RG, Cremers SC, Ball LM, Lankester AC, Teepe-Twiss IM et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005; 35: 17–23.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cure Domiciliari e Terapia cellulare, AOU, Meyer, Firenze, Italy

    D Caselli

  2. Oncoematologia Pediatrica, Ospedale dei Bambini ‘G. Di Cristina’, ARNAS Civico, Palermo, Italy

    O Ziino

  3. Unit of Pharmacokinetics, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

    A Bartoli

  4. Neuropsichiatria infantile, Ospedale dei Bambini ‘G. Di Cristina’, ARNAS Civico, Palermo, Italy

    G Santangelo & F Vanadia

  5. Dipartimento Onco-Ematologia Pediatrica, AOU, Meyer, Firenze, Italy

    D Caselli & M Aricò

Authors
  1. D Caselli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O Ziino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Bartoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Santangelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Vanadia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Aricò
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Aricò.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caselli, D., Ziino, O., Bartoli, A. et al. Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan. Bone Marrow Transplant 42, 135–136 (2008). https://doi.org/10.1038/bmt.2008.91

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.91

This article is cited by

Search

Advanced search

Quick links